French National Registry Describes Somatropin Efficacy, Safety, and Compliance in GHD Adults
Background
Growth Hormone Deficiency (GHD) in adults is a chronic condition leading to various metabolic and quality-of-life impairments. Replacement therapy with somatropin is the standard of care, aiming to restore physiological GH levels. However, real-world data on long-term efficacy, safety, and patient compliance in specific populations, like those in France, are crucial for optimizing clinical practice. Registries provide valuable insights into these aspects beyond controlled clinical trials, addressing gaps in understanding real-world treatment outcomes.
Study Design
This study extracted data from the French National Registry of adults with Growth Hormone Deficiency (GHD) who initiated somatropin therapy. The registry collects real-world information on patients receiving somatropin (Norditropin® SimpleXx®). Objectives included describing patient characteristics, assessing the efficacy and safety of somatropin, and evaluating treatment compliance in a national cohort. No specific intervention was administered; data were retrospectively analyzed from existing patient records within the registry.
Why It Matters
Real-world data from national registries are critical for understanding the long-term impact of somatropin therapy in diverse patient populations. This registry provides a framework to monitor the effectiveness and safety of somatropin (Norditropin® SimpleXx®) under routine clinical conditions, which often differ from controlled trial settings. Future analyses from this registry will inform clinicians on optimal dosing strategies, identify potential safety signals, and highlight factors influencing patient adherence, ultimately refining treatment protocols for adults with Growth Hormone Deficiency in France and potentially beyond.
somatropin
growth hormone deficiency
ghd
registry
observational
europe